Truxima (biosimilar rituximab) has been approved for marketing by the European Medicines Agency for use in all indications of its reference product MabThera, the blockbuster monoclonal antibody marketed by Roche (ROG: SIX).
Developed by South Korean firm Celltrion Healthcare (Kosdaq: 068270), Truxima is the first biosimilar monoclonal antibody approved in an oncology indication anywhere.
The product will be launched in many European countries by privately-held UK firm Mundipharma. It will be the second biosimilar of this type to be commercialized by the firm in Europe, following the launch of Remsima (infliximab) in 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze